

Overall Survival Depends on K-Ras Mutation Status in Patients with Colorectal Cancer

Contribution to YSC Davos 2008

Thematic topic: Medicine

Thomas Winder^{1,5,6}, Axel Mündlein^{5,6}, Simone Rhomberg^{5,6}, Klaus Dirschmid⁴, Bernd L. Hartmann¹, Heinz Drexel^{1,5,6}, Etienne Wenzl², Alexander De Vries³, Felix Offner⁴ and Alois Lang^{1,5}

¹ Department of Medicine, Academic Teaching Hospital Feldkirch, A-6800 Feldkirch, Austria

² Department of Surgery, Academic Teaching Hospital Feldkirch, A-6800 Feldkirch, Austria

³ Department of Radiotherapy, Academic Teaching Hospital Feldkirch, A-6800 Feldkirch, Austria

⁴ Department of Pathology, Academic Teaching Hospital Feldkirch, A-6800 Feldkirch, Austria

⁵ Vorarlberg Institute for Vascular Investigation, A-6800 Feldkirch, Austria

⁶ University of Human Sciences in the Principality of Liechtenstein, FL-9495 Triesen, Principality of Liechtenstein

Key words: colorectal cancer, overall survival, K-Ras, Kirsten-Ras, molecular markers

INTRODUCTION/BACKGROUND

Colorectal cancer (CRC) is the second most common incidental form of cancer, with 376 400 new cases diagnosed and 203.700 related deaths annually in Europe. Genetics play a key role in predisposition, initiation and progression of CRC. The multistep progression from normal colon epithelium to adenomatous polyp and finally to invasive cancer is characterized by two classes of genes, tumor-suppressor genes and proto-oncogenes (Fearon, ER and Vogelstein, B 1990). In this context, mutations in the proto-oncogene Kirsten-Ras (K-Ras) are involved in 22 – 46 % of colorectal carcinogenesis.

Mutations in the K-Ras gene, especially a glycine to valine substitution at codon 12 (G12V), has been proposed to be an independent risk factor for reduced overall survival in colorectal cancer patients (Andreyev, HJ, et al. 2001). Moreover, recent data has shown that mutations activating the Ras signalling pathway are also predictive for response to anti epidermal growth factor receptor (EGFR) monoclonal antibodies. The presence of mutations in the K-Ras gene has been associated with the lack of response to anti-EGFR monoclonal antibody treatment (Amado, RG, et al. 2008). Thus, there is increasing clinical relevance in the detection of mutations in the K-Ras gene with sensitive molecular methods to improve risk stratification and therapeutic strategies.

However, experimental in vitro data suggest that codon 12 K-Ras mutations differ in carcinogenic potential and prognostic significance. Previous studies merely showed G12V mutation to be an independent risk factor for reduced overall survival. Therefore, we aimed to further elucidate the role of different K-Ras mutations in overall survival in a large, homogenous patient cohort with standardized therapy and uniform analysis of K-Ras mutation status. We investigated the association between G12V and other K-Ras mutations, considering the fact that different mutations may show different effects on overall survival.

MATERIAL & METHODS

We considered 342 patients with histologically proven colorectal cancer at the Department for Pathology at the Academic Teaching Hospital Feldkirch from January 2003 to October 2006. Inclusion criteria were histologically confirmed colorectal cancer and patients undergoing radical surgery. After appropriate investigational review board approval, these 342 formalin fixed, paraffin embedded tissue blocks were recovered. All tumors were graded by an experienced pathologist using the UICC classification. Sections were cut from regions of the tumor containing as high a proportion of tumor cells as possible (typically $\geq 50\%$). All materials were unlinked from their identifiers before being subjected to DNA extraction and genetic analysis. Clinicopathological variables of the patients were gender, age, tumor localisation, UICC stage, and K-Ras status. Follow-up survival data were provided by the Federal Agency for Statistics in Austria.

Genomic DNA was extracted from deparaffinized tumor tissue samples using the peqGOLD® Tissue DNA Mini Kit (PEQLAB Biotechnologie Ltd., Erlangen, Germany) according to the manufacturer's instructions. Mutation analysis of K-Ras codons 12, 13, and 61 was carried out by direct sequencing of amplified PCR-products spanning respective codons.

Overall survival was defined as the time from histopathological diagnosis to death from any cause. Univariate and multivariate analysis was performed using Cox's model for proportional hazards survival analysis. Hazard ratios (HR) and 95 % confidence intervals (CI) of the hazard ratios were calculated from the individual Cox multivariate analysis. P values < 0.05 were considered to indicate statistical significance. Statistical analyses were performed with the software package SPSS 11.5 for Windows (SPSS, Inc., Chicago, IL, USA).

RESULTS

We enrolled 342 patients from an Austrian cohort with colorectal cancer diagnosed during January 2003 and October 2006. Over a mean follow up period of 26 months (± 13), 57 deaths were recorded; 54 of them were tumor related. Follow up data were not available in 17 patients (5 %). Genotyping revealed an overall mutation frequency of 28 % ($n = 96$) in K-Ras gene codons 12, 13, and 61. The most common mutation was a G to A change at codon 12 resulting in a glycine to aspartate substitution (G12D).

We analyzed the effect of each individual mutation compared to the wild type. Results from Cox regression analysis are shown in Figure 1. The G12V mutation showed a significant risk for decreased overall survival ($p = 0.022$). Mutations other than G12V ($n = 72$) showed only a moderate, non-significant effect on overall survival. However, by combining other mutations than G12V a significant protective effect on overall survival could be observed ($p = 0.046$). Concordantly, due to the contrary effect of K-Ras mutations, the G12V mutation compared to the wild type together with other mutations showed worst overall survival (HR = 2.95 [1.34 – 6.53]; $p = 0.007$). In the same way, best overall survival was observed by merged remaining mutations compared to the wild type together with the G12V mutation (HR = 0.4 [0.18 – 0.89]; $p = 0.024$). Adjustment for age, gender, and UICC tumor stage in multivariate Cox regression analysis confirmed these results (HR = 2.42 [1.07 – 5.46]; $p = 0.033$ and HR = 0.31 [0.14 – 0.7]; $p = 0.005$, respectively).




Fig.1: Results from Cox regression analysis of each individual mutation compared to the wild type. The G12R, G12A and Q61H mutations were excluded from individual Cox regression analysis because no fatalities occurred. HR; hazard ratio, CI; confidence interval (95%) Hazard ratios were calculated by Cox regression analysis.

CONCLUSIONS & OUTLOOK

Our study provides new insights into the influence of K-Ras mutations on overall survival in patients with colorectal cancer. In contrast to G12V mutation, combined remaining mutations at codons 12, 13, and 61 showed a benefit on overall survival.

Genotype frequencies in the presented study are concordant with literature reports showing K-Ras was mutated in 22 – 46 % of sporadic colorectal cancers. However, reported prognostic impact of the K-Ras mutations provided inconsistent results. A large meta-analysis suggested that the G12V mutation at codon 12 in the K-Ras gene increases the risks of recurrence or death in patients with colorectal cancer (Andreyev, HJ, et al. 2001). These data are supported by our findings that G12V mutation affects overall survival. Earlier studies could not demonstrate a significant impact on overall survival of other K-Ras mutations. However, in our study, K-Ras mutations other than G12V, showed a moderate, but non-significant effect on overall survival. By combining these mutations a clear survival benefit was observed.

In vitro studies showed that different Ras mutations may influence the oncogenesis unequally because of their different effects on signal transduction mechanisms (Al Mulla, F, et al. (1999). Normal Ras cycle occurs between a GDP bound inactive and a GTP bound active form of Ras. Mutant Ras remain longer in the GTP-bound state, resulting in a more persistent growth signal. It is proposed that lower affinity of GTP to G12D allows G12D an escape from the oncogenic GTP-bound state, whereas GTP tightly bound to G12V generates a more persistent, potentially oncogenic signal. Furthermore, differences in the effector region of G12D und G12V could modify interactions with downstream signalling molecules. Due to

these effects, the influence of different K-Ras mutations on overall survival might be explained by the fact that heterogeneity of K-Ras mutations in colorectal cancer may differ in carcinogenic potential.

Additionally, K-Ras is a potential biomarker for anti-epidermal growth factor (EGFR) targeted treatment of metastatic colorectal cancer (mCRC) patients (Amado, RG, et al. 2008). Prospective randomized studies are ongoing to elucidate the impact of different K-Ras mutations on antibody treatment in combination with chemotherapy. Findings of these studies offer the possibility to adapt therapy to each patient's individual K-Ras mutational status. Consequently, potential adverse effects of treatment can be avoided and leads to cost reduction of increasingly limited financial funds

To the best of our knowledge this is the first report with the largest sample size showing antidromic effects of nonsynonymous mutations of the K-Ras gene on overall survival. In contrast to other studies we provide several advantages for the investigation of the role of K-Ras mutations on overall survival in colorectal cancer patients: All patients were diagnosed centrally; the patient cohort was homogeneous and regionally restricted; standardized therapy was offered to all patients with colorectal cancer; there was uniform analysis of K-Ras mutations on codon 12, 13 and 61. Using these methods, the relationship between the genetic profile of colorectal cancer and overall survival can be reliably assessed.

In conclusion, our results suggest that different mutations on the K-Ras gene show different effects on overall survival in patients with colorectal cancer. G12V mutation affects overall survival adverse, whereas other mutations influence overall survival favourable as we could show for the first time. Further studies are in progress to elucidate the impact of each individual K-Ras mutational status with respect to treatment.

REFERENCES

- Fearon, ER and Vogelstein, B (1990), 'A genetic model for colorectal tumorigenesis', *Cell*, 61(5), 759-67.
- Andreyev, HJ, et al. (2001), 'Kirsten ras mutations in patients with colorectal cancer: the 'RASCAL II' study', *British Journal of Cancer*, 85 (5), 692-6.
- Amado, RG, et al. (2008), 'Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer', *Journal of Clinical Oncology*, 26 (10), 1626-34.
- Al Mulla, F, et al. (1999), Structural differences between valine-12 and aspartate-12 Ras proteins may modify carcinoma aggression', *Journal of Pathology*, 187 (4), 433-38.